BRIEF-Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease

Reuters
04 Feb
BRIEF-Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease

Feb 4 (Reuters) - Cumberland Pharmaceuticals Inc CPIX.O:

  • CUMBERLAND PHARMACEUTICALS ANNOUNCES BREAKTHROUGH RESULTS FROM THE PHASE 2 FIGHT DMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY HEART DISEASE

  • CUMBERLAND PHARMACEUTICALS INC - IFETROBAN WELL-TOLERATED WITH NO SERIOUS DRUG-RELATED EVENTS

Source text: ID:nPn9B7wCBa

Further company coverage: CPIX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10